Transcription Factor 21 (TCF21) rs12190287 Polymorphism is Associated with Osteosarcoma Risk and Outcomes in East Chinese Population
Zhenghui Jiang, Weikang Zhang, Zhikang Chen, Jinxiang Shao, Liqiu Chen, Zhaohui Wang
Department of Orthopaedics, The First People’s Hospital of Wenling, Wenling, Zhejiang, China (mainland)
Med Sci Monit 2017; 23:3185-3191
The transcription factor 21 (TCF21) gene is believed to be a tumor suppressor gene. TCF21 gene polymorphisms were found to play a role in the tumorigenesis of some solid malignancies. We raised a hypothesis that genetic polymorphisms of TCF21 were correlated with risk and prognosis of osteosarcoma.
MATERIAL AND METHODS: We recruited 225 young osteosarcoma individuals and 250 cancer-free controls. Five tagging SNPs (TCF21 rs2327429 T>C, rs2327433 A>G, rs2327433 A>G, rs12190287 C>G, and rs4896011 T>A) were genotyped. Preserved DNA samples from blood underwent PCR analysis for genotyping.
RESULTS: rs12190287 C>G is a good predictor of osteosarcoma risk and outcomes. The CG and GG genotypes of rs12190287 predict elevated risk of osteosarcoma. Besides, rs12190287 CG and GG genotypes are associated with Enneking stage and potential in forming metastasis of osteosarcoma.
CONCLUSIONS: Genetic polymorphisms of TCF21 are potentially predictive for osteosarcoma risk and outcomes.
Keywords: Osteosarcoma, Polymorphism, Single Nucleotide, Prognosis